Investors

News Releases

Date Title  
Toggle Summary Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index
MILTON, ONTARIO -- (Marketwired) -- 04/15/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX )(OTCQX: TBUFF ) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and
Toggle Summary Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Investor Conference
MILTON, ONTARIO -- (Marketwired) -- 04/27/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary POZEN Announces May 8th Webcast of First Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--May 4, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2015 results on May 8, 2015 , before the market opens.
Toggle Summary POZEN Reports First Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--May 8, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2015 . Corporate Highlights Q1 2015 was the fourth consecutive quarter of
Toggle Summary Tribute Pharmaceuticals Schedules First Quarter 2015 Financial Results Conference Call
MILTON, ONTARIO -- (Marketwired) -- 05/08/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals Announces First Quarter 2015 Results
Revenue Up 60%, EBITDA Up 116% Over Comparative Period MILTON, ONTARIO -- (Marketwired) -- 05/12/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor(R) and Commercial Expansion into U.S. Market
- William Maichle Hired as President of U.S. Operations MILTON, ONTARIO -- (Marketwired) -- 05/21/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF )(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing,
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor®, Commercial Expansion into U.S. Market and Completion of $12 Million Equity Financing
- William Maichle Hired as President of U.S. Operations MILTON, ONTARIO--(Marketwired - May 21, 2015) - NOT FOR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty
Toggle Summary POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 1, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, effective
Toggle Summary POZEN Forms an Irish Subsidiary and Enters into an Intangible Property Transfer Arrangement
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 2, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to developing medicine that transforms lives, today announced that it has formed POZEN Limited , a wholly owned Irish subsidiary and has entered in an Intangible Property Transfer

Copyright West LLC. Minimum 15 minutes delayed.